Immunotherapy treats Ca based on genetic feature – ModernMedicine
|
Immunotherapy treats Ca based on genetic feature
ModernMedicine The immunotherapy agent pembrolizumab (Keytruda) was recently approved by the FDA for treating any cancers that exhibit DNA mismatch repair deficiency, marking the first time the agency has approved a cancer treatment based on a biomarker rather than … |
